Keywords: Agenus, Braind cancer, Vaccine, Glioblastoma Multiforme, Ph II
Agenus brain cancer vaccine improves survival in Ph II
Article | 22 April 2012
USA-based Agenus (Nasdaq: AGEN) says that a Phase II multicenter trial of its autologous heat shock protein-peptide vaccine (HSPPC-96; vitespen) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
